ReviewJournal of thoracic disease2026
The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: a narrative review.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: The historical management of resectable non-small cell lung cancer (NSCLC) has relied on surgical resection and adjuvant chemotherapy, an approach with unsatisfactory long-term survival due to high rates of recurrence and micrometastasis. This narrative review synthesizes the evidence for a paradigm shift to neoadjuvant immunotherapy, which administers systemic therapy prior to surgery to address both the primary tumor and subclinical micrometastatic disease. Methods: A comprehensive review was conducted on PubMed, Embase, and Scopus, limited to English-language articles from 2018 to the present to ensure a focus on recent, pivotal Phase II and III randomized clinical trials. The search used keywords such as 'neoadjuvant immunotherapy', 'resectable NSCLC', and 'biomarkers' to identify relevant studies. Key Content and Findings: Initial immune checkpoint inhibitor (ICI) monotherapy trials established feasibility and efficacy. Large-scale phase III trials like CheckMate 816 and AEGEAN have since established neoadjuvant chemo-immunotherapy as the new standard of care, demonstrating significant improvements in pathological complete response (pCR), event-free survival (EFS), and overall survival (OS). This has validated pathological response as a surrogate endpoint for long-term survival, which accelerates drug development. The review also highlights novel combinations like antibody-drug conjugates (ADCs) in trials such as NeoCOAST-2, which have shown high pathological response rates, and discusses the evolution of biomarkers from programmed death-ligand 1 (PD-L1) to the more dynamic circulating tumor DNA (ctDNA). Conclusions: Neoadjuvant immunotherapy has fundamentally transformed the treatment landscape for resectable NSCLC, establishing a definitive paradigm shift from conventional surgery-first approaches and becoming a foundational component of modern multidisciplinary care with a promising trajectory toward improved long-term outcomes and the realization of minimal residual disease (MRD) guided therapy. Challenges remain, including the need for better predictive biomarkers, optimized regimens, and management of surgical complexities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.